Foundayo® is a once-daily prescription tablet containing orforglipron, a GLP-1 receptor agonist. It is licensed for weight loss and weight maintenance in adults with a BMI of 30 or above, or a BMI between 27 and 30 with at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity. The same MHRA authorisation also covers improving blood sugar control in adults with insufficiently controlled type 2 diabetes.
GLP-1 receptor agonists mimic a hormone the body releases after eating. Orforglipron acts on the areas of the brain that regulate appetite, helping people feel fuller for longer, reducing hunger and decreasing food cravings — so they eat less alongside appropriate diet and lifestyle measures.
In the UK, Foundayo® is only available following a clinical assessment. It is not currently available on the NHS; that decision follows a separate evaluation by NICE.
Why Foundayo® Benefits you need to know aboutNo fasting window — take it whenever suits you
Foundayo® is the only GLP-1 pill that can be taken at any time of day, with or without food and with no water restrictions. Orforglipron is a small molecule rather than a peptide, so it does not need an absorption enhancer or an empty stomach — which is why it avoids the 30-minute morning wait required by oral semaglutide.
No needles — a daily tablet instead
For people who would rather not inject, Foundayo® offers GLP-1 treatment in a once-daily oral form. No pens, no needles, no sharps disposal and no refrigerated delivery.
Weight loss proven in a large phase 3 programme
Across two 72-week registration trials enrolling more than 4,500 adults, orforglipron produced significantly greater weight loss than placebo at every dose studied — up to 25 lb, around 11 kg or 11.1% of body weight, in adults without diabetes on the 17.2 mg dose.
Improvements in other health measures
Adults taking orforglipron alongside diet and exercise also saw improvements in waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure. These findings are from clinical trial data; Foundayo® is not licensed to treat cholesterol or blood pressure.
Greater fat mass loss than lean mass loss
Trial data indicate the weight reduction seen with orforglipron involves greater loss of fat mass than lean mass. This result is based on a less rigorous assessment and may be due to chance.
Foundayo® is backed by the ATTAIN phase 3 programme. Here is what the evidence shows.
| 17.2 mg at 72 weeks | Placebo |
|---|---|
| 11.1% average weight loss — up to 25 lb (11 kg) | 2.1% average weight loss — 5.3 lb (2.4 kg) |
In ATTAIN-1, a 72-week trial in adults with obesity or overweight and a weight-related condition but without diabetes, average body weight loss was 7.4% on the 5.5 mg dose, 8.3% on 9 mg and 11.1% on 17.2 mg, compared with 2.1% on placebo. Based on an average starting weight of 227 lb (about 103 kg), that is up to 25 lb — around 11 kg, or roughly 1 st 11 lb — on the highest dose.
About 1 in 5 adults (18.4%) taking the 17.2 mg dose lost 20% or more of their body weight — roughly 45 lb — compared with 2.9% of those on placebo. Among the 1,127 participants who had prediabetes when they joined the study, up to 91% reached near-normal blood sugar levels by 72 weeks, versus 42% on placebo.
ATTAIN-1 randomised 3,127 adults across nine countries to one of three orforglipron doses or placebo, all alongside a reduced-calorie diet and increased physical activity. Participants had obesity, or overweight with at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or cardiovascular disease. Adults with diabetes were excluded.
ATTAIN-2 studied 1,613 adults with a BMI of 27 kg/m² or above and type 2 diabetes across 136 sites in ten countries. Average weight loss was 5.1%, 7.0% and 9.6% across the three doses versus 2.5% on placebo, and HbA1c fell by 1.3–1.8% from an average baseline of 8.1%.
Eligibility is confirmed during your free online consultation.
✓ You may be eligible if...
- BMI of 30 or above
- BMI between 27 and 30 with at least one weight-related condition
- Aged 18 or over
- Not pregnant, breast-feeding or trying to conceive
- Able to follow dietary and lifestyle guidance
✗ May not be suitable if...
- You are pregnant, breast-feeding or trying to conceive
- You have type 1 diabetes
- You are already taking another GLP-1 receptor agonist
- You have a history of pancreatitis
- You have a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
- You have a known hypersensitivity to orforglipron
One tablet, once a day — and that is the whole routine. There is no fasting window and no waiting period.
- Take Foundayo® by mouth once each day, with or without food, at any time of day.
- Swallow tablets whole. Do not break, crush or chew the tablet.
- Do not take more than 1 tablet per day.
- If you miss a dose, take it as soon as possible — but never take two doses on the same day.
- If you miss taking Foundayo® for 7 or more days in a row, contact your prescriber about restarting.
Storing your Foundayo® tablets
Store at room temperature, 20°C–25°C (68°F–77°F). Foundayo® is sensitive to light — keep it in the original bottle and carton and replace the cap after each use. If you no longer have the carton, store the bottle away from light. No refrigeration required. Keep out of reach of children.
Treatment begins at 0.8 mg and steps up gradually, with a minimum of one month at each dose level, up to a maximum of 17.2 mg once daily. Gradual escalation gives your body time to adjust and helps minimise side effects.
| Stage | Dose | Minimum duration |
|---|---|---|
| Starter | 0.8 mg once daily | At least 30 days |
| Titration | 2.5 mg once daily | At least 30 days |
| Titration | 5.5 mg once daily | At least 30 days |
| Titration | 9 mg once daily | At least 30 days |
| Titration | 14.5 mg once daily | At least 30 days |
| Maintenance | 17.2 mg once daily | Maximum dose |
Like all prescription medicines, Foundayo® can cause side effects. Most are gastrointestinal, mild to moderate, and improve over time — particularly after dose increases. This does not replace the full SmPC or your prescriber's advice.
Most common side effects
Nausea • Constipation • Diarrhoea • Vomiting • Dyspepsia (indigestion) • Abdominal pain
Also reported in clinical trials
Headache • Abdominal distension • Fatigue • Belching • Heartburn • Wind • Hair loss • Increased resting heart rate
Serious — seek urgent medical advice
Severe or persistent stomach problems • Dehydration leading to kidney problems • Acute pancreatitis • Severe allergic reaction • Neck lump or swelling, hoarseness, trouble swallowing or shortness of breath
For urgent symptoms contact NHS 111. For emergencies call 999. Report adverse events to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.
In the trials, around 3–6% of people stopped treatment because of gastrointestinal side effects, compared with 0.7% on placebo. Do not take Foundayo® if you or any family member have ever had medullary thyroid carcinoma, or if you have Multiple Endocrine Neoplasia syndrome type 2.
FAQs Frequently Asked QuestionsBe the First to Know When Foundayo® Launches
Foundayo® was authorised by the MHRA on 10 August 2026 and is expected to reach UK pharmacies in the coming weeks. Register your interest and we will let you know as soon as it is available to order.
Register Your Interest → Happy Pharmacy is a GPhC-registered pharmacy (No. 9012585) — Superintendent Pharmacist: Palvinder Deol — Rated 4.8★ Excellent on Trustpilot- MHRA. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes. 10 August 2026.
- Wharton S et al. ATTAIN-1. N Engl J Med, September 2025.
- Horn DB et al. ATTAIN-2. The Lancet, 2025.
- Foundayo® (orforglipron) prescribing information, Eli Lilly and Company.
- Foundayo® Summary of Product Characteristics and Patient Information Leaflet, MHRA Products website.